Incyte (INCY) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
August 3, 2021 7:00 AM EDT- Total product and royalty revenues of $696 million in Q2 2021 (+17% vs Q2 2020)
- Jakafi® (ruxolitinib) revenues of $529 million in Q2 2021 (+12% vs Q2 2020)
- Positive CHMP opinion for tafasitamab in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
- Phase 3 TRuE-V1 and TRuE-V2 studies evaluating ruxolitinib cream in vitiligo met primary and key secondary endpoints
Conference Call and Webcast Scheduled Today at 8:00 a.m. EDT
WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq: INCY)... More
